Latest Pharma Insights
- Filter
- All Sources
- Scrip
- The Pink Sheet
- IN VIVO
- Medtech Insight
- The Rose Sheet
- Strategic Transactions
Challenges Prompt Canada To Adapt MDSAP Transition Plan
Health Canada is making it easier for device manufacturers to transition to the Medical Device Single Audit Program by the...
Medtech Insight - April 19, 2018
Health Canada is making it easier for device manufacturers to transition to the Medical Device Single Audit Program by the...
Medtech Insight - April 19, 2018
Germany and France Round On European Commission HTA Cooperation Proposals
Plans from the European Commission that would oblige all EU member states to consider joint clinical assessments have come under...
The Pink Sheet - April 19, 2018
Plans from the European Commission that would oblige all EU member states to consider joint clinical assessments have come under...
The Pink Sheet - April 19, 2018
Publisher's Spotlight: The 2018 Scrip Awards Is Now Open For Entries
Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for...
Scrip - April 19, 2018
Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for...
Scrip - April 19, 2018
Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater...
Scrip - April 19, 2018
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater...
Scrip - April 19, 2018
Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements...
Scrip - April 19, 2018
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements...
Scrip - April 19, 2018
VIDEO: Novo Seeds: Investing In Biopharma Growth
Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how...
Scrip - April 19, 2018
Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how...
Scrip - April 19, 2018
Experts Challenge GSK Triple Inhaled COPD Therapy Claims
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with...
Scrip - April 19, 2018
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with...
Scrip - April 19, 2018
TVM Raises White Flag On Biovertis & Morphochem
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4%...
Scrip - April 19, 2018
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4%...
Scrip - April 19, 2018
BenevolentAI Scoops $115M For AI Drug Development
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug...
Scrip - April 19, 2018
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug...
Scrip - April 19, 2018
QUOTED. April 19, 2018. Abel Ang.
For device-makers that want to capitalize on opportunities arising from Asia's ever-burgeoning health-care systems, relationships are indeed critical to a...
Medtech Insight - April 19, 2018
For device-makers that want to capitalize on opportunities arising from Asia's ever-burgeoning health-care systems, relationships are indeed critical to a...
Medtech Insight - April 19, 2018
INFOGRAPHIC: China Vs Cancer: An Infographic Snapshot
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising...
Scrip - April 19, 2018
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising...
Scrip - April 19, 2018
Publisher's Spotlight: The 2018 Scrip Awards Is Now Open For Entries
Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for...
Scrip - April 19, 2018
Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for...
Scrip - April 19, 2018
Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater...
Scrip - April 19, 2018
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater...
Scrip - April 19, 2018
Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements...
Scrip - April 19, 2018
This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements...
Scrip - April 19, 2018
VIDEO: Novo Seeds: Investing In Biopharma Growth
Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how...
Scrip - April 19, 2018
Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how...
Scrip - April 19, 2018
Experts Challenge GSK Triple Inhaled COPD Therapy Claims
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with...
Scrip - April 19, 2018
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with...
Scrip - April 19, 2018
TVM Raises White Flag On Biovertis & Morphochem
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4%...
Scrip - April 19, 2018
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4%...
Scrip - April 19, 2018
BenevolentAI Scoops $115M For AI Drug Development
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug...
Scrip - April 19, 2018
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug...
Scrip - April 19, 2018
INFOGRAPHIC: China Vs Cancer: An Infographic Snapshot
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising...
Scrip - April 19, 2018
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising...
Scrip - April 19, 2018
Germany and France Round On European Commission HTA Cooperation Proposals
Plans from the European Commission that would oblige all EU member states to consider joint clinical assessments have come under...
The Pink Sheet - April 19, 2018
Plans from the European Commission that would oblige all EU member states to consider joint clinical assessments have come under...
The Pink Sheet - April 19, 2018
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent...
IN VIVO - April 18, 2018
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent...
IN VIVO - April 18, 2018
How Healthy Is Your Growth Strategy? Five Principles To Fight Complexity In Today’s Medtech And Biopharma Enterprise
Top performers in today’s health care market are transforming their growth strategies. They excel at category leadership, cost reduction and...
IN VIVO - April 18, 2018
Top performers in today’s health care market are transforming their growth strategies. They excel at category leadership, cost reduction and...
IN VIVO - April 18, 2018
Challenges Prompt Canada To Adapt MDSAP Transition Plan
Health Canada is making it easier for device manufacturers to transition to the Medical Device Single Audit Program by the...
Medtech Insight - April 19, 2018
Health Canada is making it easier for device manufacturers to transition to the Medical Device Single Audit Program by the...
Medtech Insight - April 19, 2018
QUOTED. April 19, 2018. Abel Ang.
For device-makers that want to capitalize on opportunities arising from Asia's ever-burgeoning health-care systems, relationships are indeed critical to a...
Medtech Insight - April 19, 2018
For device-makers that want to capitalize on opportunities arising from Asia's ever-burgeoning health-care systems, relationships are indeed critical to a...
Medtech Insight - April 19, 2018
Artelo gets worldwide rights to Stony Brook Univ. IP
Stony Brook University licensed Artelo Biosciences Inc. intellectual property related to fatty acid binding protein (FABP) inhibitors having potential in treating various conditions such as cancer, inflammation, and pain.
Strategic Transactions - April 18, 2018
Stony Brook University licensed Artelo Biosciences Inc. intellectual property related to fatty acid binding protein (FABP) inhibitors having potential in treating various conditions such as cancer, inflammation, and pain.
Strategic Transactions - April 18, 2018
Clovis completes public debt and stock offerings; nets $386mm
Clovis Oncology Inc. (developing cancer drugs and companion diagnostics) netted $386mm through concurrent debt and stock offerings. In the first transaction, the company issued $300mm principal amount (net $292mm) of its 1.25% senior notes due 2025, which convert to common at a rate of 13.1278 shares per $1k (or $76.17 per share). Clovis also sold 1.8mm of its common shares at $54.41 for net proceeds of $94. Funds from both offerings will support ongoing corporate needs, including marketing expenses associated with Rubraca (rucaparib) for ovarian cancer in the US (and Europe, once approved).
Strategic Transactions - April 18, 2018
Clovis Oncology Inc. (developing cancer drugs and companion diagnostics) netted $386mm through concurrent debt and stock offerings. In the first transaction, the company issued $300mm principal amount (net $292mm) of its 1.25% senior notes due 2025, which convert to common at a rate of 13.1278 shares per $1k (or $76.17 per share). Clovis also sold 1.8mm of its common shares at $54.41 for net proceeds of $94. Funds from both offerings will support ongoing corporate needs, including marketing expenses associated with Rubraca (rucaparib) for ovarian cancer in the US (and Europe, once approved).
Strategic Transactions - April 18, 2018
RubrYc closes $10mm Series A
Antibody drug discovery firm RubrYc Therapeutics Inc. raised $10mm in its Series A financing led by Third Point Ventures, which was joined by Paladin Capital Group and Vital Venture Capital.
Strategic Transactions - April 18, 2018
Antibody drug discovery firm RubrYc Therapeutics Inc. raised $10mm in its Series A financing led by Third Point Ventures, which was joined by Paladin Capital Group and Vital Venture Capital.
Strategic Transactions - April 18, 2018
Advent International enters agreements to buy Zentiva from Sanofi for €1.9bn
Sanofi confirmed that is in exclusive negotiations to divest its European generics business Zentiva BV to private equity firm Advent International for €1.9bn ($2.3bn). The deal is said to be binding and fully financed, and could close by the end of year, pending definitive agreements and regulatory approval.
Strategic Transactions - April 18, 2018
Sanofi confirmed that is in exclusive negotiations to divest its European generics business Zentiva BV to private equity firm Advent International for €1.9bn ($2.3bn). The deal is said to be binding and fully financed, and could close by the end of year, pending definitive agreements and regulatory approval.
Strategic Transactions - April 18, 2018
